Tyrosine kinase 2 and Janus kinase?signal transducer and activator of transcription signaling and inhibition in plaque psoriasis - 09/12/21
Abstract |
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase-signal transducer and activator of transcription pathway plays a major role in intracellular cytokine signaling in inflammatory processes involved in psoriasis. Although Janus kinase (JAK) 1-3 inhibitors have demonstrated efficacy in patients with moderate-to-severe psoriasis, safety concerns persist and no JAK inhibitor has received regulatory approval to treat psoriasis. Thus, an opportunity exists for novel oral therapies that are safe and efficacious in psoriasis. Tyrosine kinase 2 (TYK2) is a member of the JAK family of kinases and regulates signaling and functional responses downstream of the interleukin 12, interleukin 23, and type I interferon receptors. Deucravacitinib, which is an oral, selective inhibitor that binds to the regulatory domain of TYK2, and brepocitinib (PF-06700841) and PF-06826647, which are topical and oral TYK2 inhibitors, respectively, that bind to the active (adenosine triphosphate-binding) site in the catalytic domain, are in development for psoriasis. Selective, allosteric inhibition of TYK2 signaling may reduce the potential for toxicities associated with pan-JAK inhibitors. This article reviews Janus kinase-signal transducer and activator of transcription and TYK2 signaling and the efficacy and safety of JAK inhibitors in psoriasis to date, focusing specifically on TYK2 inhibitors.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : cytokine signaling, immune-mediated inflammatory disease, inhibition, Janus kinase-signal transducer, plaque psoriasis, TYK2
Abbreviations used : AE, IFN, IL, IMID, JAK, JAK-STAT, PASI, PsA, RA, SLE, TYK2
Plan
Funding sources: Sponsored by Bristol Myers Squibb. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 86 - N° 1
P. 148-157 - janvier 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?